Investigational COVID-19 vaccine well-tolerated and generates immune response in older adults
30 Sep, 2020 | 09:36h | UTCOriginal Article: Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults – New England Journal of Medicine
Commentary on Twitter
The Moderna mRNA vaccine, which elicited antibodies and T cells specific for the Covid-19 virus in adults 55 years of age or younger, elicited similarly high levels of neutralizing-antibody and CD4 T-cell responses in older adults. #COVID19 #SARSCoV2
— NEJM (@NEJM) September 29, 2020